Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome characterized by oligo- or anovulation, clinical and/or biochemical signs of hyperandrogenemia and polycystic ovaries. Clinical expression is determined by both genetic and environmental factors. Dyslipidemia is very common in lean as well as in obese women with PCOS and should be considered in the therapeutic management of the syndrome. Additionally to dyslipidemia, other risk factors for cardiovascular disease strongly associated with PCOS include insulin resistance, impaired glucose tolerance and metabolic syndrome. Therefore, the ideal therapeutic approach for PCOS would be multi targeted treatment ameliorating not only ovarian dysfunction but also cardiometabolic aspects, including dyslipidemia. Recently, a new era of hypolipidemic agents like statins has been initiated with regard to PCOS. The spectrum of statins targets has been expanded and in vitro and in vivo studies have explored the specific effect of statins on androgen production, insulin resistance and inflammatory markers in PCOS. Statins are potentially promising therapeutic agents targeting hormonal and metabolic disturbances in PCOS, though conclusive results are still pending. Since several hormonal and metabolic aberrations characterizing this multifaceted syndrome cluster and interact with each other, their effects on the lipid profile are interweaving and the therapeutic modalities targeting dyslipidemia appear to have a more broad beneficial effect.
Keywords: Polycystic ovary syndrome, dyslipidemia, statins, antiandrogens, insulin sensitizers, anovulation, hyperandrogenemia, insulin, obesity, nosological, oligoovulation, ultrasonography, steroidogenic, phosphorylation, dihydrotestosterone, flutamide, hyperinsulinemia, fibrinogen, hirsutism, angiographic
Current Pharmaceutical Design
Title: The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond
Volume: 17 Issue: 9
Author(s): Frangiskos Economou, Xenofon Xyrafis, Charikleia Christakou and Evanthia Diamanti-Kandarakis
Affiliation:
Keywords: Polycystic ovary syndrome, dyslipidemia, statins, antiandrogens, insulin sensitizers, anovulation, hyperandrogenemia, insulin, obesity, nosological, oligoovulation, ultrasonography, steroidogenic, phosphorylation, dihydrotestosterone, flutamide, hyperinsulinemia, fibrinogen, hirsutism, angiographic
Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome characterized by oligo- or anovulation, clinical and/or biochemical signs of hyperandrogenemia and polycystic ovaries. Clinical expression is determined by both genetic and environmental factors. Dyslipidemia is very common in lean as well as in obese women with PCOS and should be considered in the therapeutic management of the syndrome. Additionally to dyslipidemia, other risk factors for cardiovascular disease strongly associated with PCOS include insulin resistance, impaired glucose tolerance and metabolic syndrome. Therefore, the ideal therapeutic approach for PCOS would be multi targeted treatment ameliorating not only ovarian dysfunction but also cardiometabolic aspects, including dyslipidemia. Recently, a new era of hypolipidemic agents like statins has been initiated with regard to PCOS. The spectrum of statins targets has been expanded and in vitro and in vivo studies have explored the specific effect of statins on androgen production, insulin resistance and inflammatory markers in PCOS. Statins are potentially promising therapeutic agents targeting hormonal and metabolic disturbances in PCOS, though conclusive results are still pending. Since several hormonal and metabolic aberrations characterizing this multifaceted syndrome cluster and interact with each other, their effects on the lipid profile are interweaving and the therapeutic modalities targeting dyslipidemia appear to have a more broad beneficial effect.
Export Options
About this article
Cite this article as:
Economou Frangiskos, Xyrafis Xenofon, Christakou Charikleia and Diamanti-Kandarakis Evanthia, The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428821
DOI https://dx.doi.org/10.2174/138161211795428821 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Flavonoid Antioxidants
Current Medicinal Chemistry Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Mechanical Thrombectomy in Acute Ischaemic Stroke: A Review of the Literature, Clinical Effectiveness and Future Use
CNS & Neurological Disorders - Drug Targets The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Metallocarboxypeptidases: Emerging Drug Targets in Biomedicine
Current Pharmaceutical Design Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Epigenetic Basis of Individual Variability to Major Psychosis
Current Pharmacogenomics and Personalized Medicine Tachykinins and Neuropsychiatric Disorders
Current Drug Targets Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Erythropoietin and Oxidative Stress
Current Neurovascular Research